Unusual Symptoms

Lab Test Genecept Assay Report Page 4 June 25, 2015


Drug Interaction Summary: Pain Medications


This summary provides a listing of implications for psychotropic medications specific to your patient's genetic profile
 
Use as Directed
Use With Caution
Medication
Primary metabolizing enzyme(s)
No known Gene-Drug Interactions
Serum levels may be ↑ [reduced dose may be required]
Serum levels may be ↓ [increased dose may be required]
Decreased prodrug conversion to active metabolite [Increased dose or alternate strategy may be required]
Increased prodrug conversion to active metabolite [decreased dose or alternate strategy may be required]
Pain
Carisoprodol (Soma®) 2C19
X
  
Codeine] 2D6
X
  
Cyclobenzaprine (Flexeril®)
-
X
  
Fentanyl 3A4
X
  
Hydrocodone[1] 2D6
X
  
Hydromorphone
-
X
  
Methadone 3A4
X
  
Methocarbamol (Robaxin®)
-
X
  
Morphine
-
X
  
Oxycodone 2D6, 3A4
X
  
Oxymorphone
-
X
  
Pregabalin (Lyrica®)
-
X
  
Tramadol (Ultram®) 2D6, 3A4
X
  

[1} Prodrug - requiring activation by the liver; 2D6 IMs/PMs may experience lower efficacy and increased side effects due to reduced conversion to the active metabolite and higher levels of the inactive parent drug; 2D6 UMs may experience increased conversion of the parent drug, and higher levels of the active metabolite
[2] Indeterminate - gene drug interaction exists, but clinical impact is indeterminate or genotype could not be determined
[4] - Medication has manufacturer dose-administration FDA labeling; see the Genecept Assay Report Interpretation Guide

*References for the Drug Interaction Summary are available upon request

TEST METHODOLOGY

This test was developed and performance characteristics were validated by Genomind. It has not been cleared or approved by the US Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Genomind performed the testing using standard and custom TaqMan reagents for all variants except for one, which was performed by PCR. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.


The genetic testing on which this report relies was performed by Genomind, 2200 Renaissance Boulevard, Suite 100, King of Prussia, PA 19406. CLIA number 39D2088097, Jeff Wisotzkey, PhD, HCLD, CC, Laboratory Director


Test Methodology Limitations:

Variants tested include SLO6A4, rs25531 and rs63749047, 5HT2C rs3813929, DRD2 rs1799732, CACNA1C rs1006737, ANK3 rs10994336, COMT rs4680, MTHFR rs1801133, CYP2D6 rs16947, rs35742686, rs3892097, gene deletion (*5), gene duplication, rs5030655, rs5030656, rs1065852, rs28371706 and rs26371725, CYP2C19 rs4244285, rs4986893 and rs12248560 and CYP3A4/5 rs776746, rs10264272 and rs41303343


THE LITERATURE INFORMATION UPON WHICH THIS REPORT RELIES WAS AGGREGATED AND REVIEWED BY GENOMIND, INC.


<- Previous


email: 

Page Revised: September 5, 2015